Loading
Led the tebentafusp trial, the first treatment ever to extend survival in metastatic uveal melanoma.
Paul Nathan (Mount Vernon Cancer Centre) was principal investigator of IMCgp100-202, the randomised trial showing the gp100-directed bispecific T-cell engager tebentafusp improves overall survival in HLA-A*02:01-positive metastatic uveal melanoma, the first drug to do so and the first approved TCR-based therapy. He has led UK melanoma and renal trials and chairs national melanoma guideline groups.
Shares gp100 (PMEL), IMCgp100-202, Tebentafusp, Uveal melanoma and the tag uveal-melanoma.
Shares Mount Vernon Cancer Centre and the tag uk.
Shares CD3, T-cell engagers (bispecific) and the tag bispecific.
Shares CD3, T-cell engagers (bispecific) and the tag bispecific.
Shares IMCgp100-202, Tebentafusp, Uveal melanoma, Melanoma.
Shares Tebentafusp, T-cell engagers (bispecific), Melanoma.
Shares Tebentafusp, CD3, Uveal melanoma, T-cell engagers (bispecific).
Shares gp100 (PMEL), Tebentafusp, CD3, Uveal melanoma.